| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Silence Therapeutics plc | EVP and Chief R&D Officer | Employee Share Option (Right to Buy) | 300,000 | 02 Jan 2026 | Direct | ||
| Dianthus Therapeutics, Inc. /DE/ | Director | Stock Option (Right to Buy) | 12,500 | 22 May 2025 | Direct | ||
| Mallinckrodt plc | EVP & Chief Sci. Ofcr | Ordinary Shares | 0 | $37.50 | 16 Jun 2022 | Direct | |
| Mallinckrodt plc | EVP & Chief Sci. Ofcr | Employee Share Options (Right to Buy) | 0 | 16 Jun 2022 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| SLN | Silence Therapeutics plc | 02 Jan 2026 | 1 | $0 | 4 | EVP and Chief R&D Officer | 06 Jan 2026, 16:15 |
| DNTH | Dianthus Therapeutics, Inc. /DE/ | 22 May 2025 | 1 | $0 | 4 | Director | 22 May 2025, 16:42 |
| SLN | Silence Therapeutics plc | 02 Jan 2025 | 1 | $0 | 4 | EVP and Chief R&D Officer | 06 Jan 2025, 16:15 |
| SLN | Silence Therapeutics plc | 02 Jan 2025 | 0 | $0 | 3 | EVP and Chief R&D Officer | 02 Jan 2025, 16:26 |
| DNTH | Dianthus Therapeutics, Inc. /DE/ | 16 Sep 2024 | 1 | $0 | 4 | Director | 18 Sep 2024, 17:38 |
| DNTH | Dianthus Therapeutics, Inc. /DE/ | 16 Sep 2024 | 0 | $0 | 3 | Director | 18 Sep 2024, 17:32 |
| /report/000089924322023426-romano-steven-j-2022-06-16 | Mallinckrodt plc | 16 Jun 2022 | 7 | $0 | 4 | EVP & Chief Sci. Ofcr | 21 Jun 2022, 18:10 |